Clinical Trials Logo

Recurrent Laryngeal Cancer clinical trials

View clinical trials related to Recurrent Laryngeal Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT03595410 Recruiting - Clinical trials for Recurrent Laryngeal Cancer

Nomograms to Precisely Predict Conditional Risk of Recurrence for Patients With Laryngeal Cancer

Start date: January 1, 2017
Phase:
Study type: Observational

Advanced laryngeal squamous cell carcinoma (SCC) remains a highly morbid and fatal disease despite aggressive interventions. Mortality is high in this cohort: laryngeal cancer affects over 13 000 patients in the United States, with over 3500 deaths annually.The results of the Veterans Affairs Cooperative Studies Program Laryngeal Cancer Trial and subsequent studies demonstrated similar overall survival (OS) rates for organ preservation protocols involving radiotherapy (RT) or chemoradiotherapy (CRT) when compared to surgery, with the benefit of preserving the larynx in a large majority of patients. As such, the use of RT or CRT has become the predominant initial intervention for patients with laryngeal SCC.6 However, the prognosis of recurrent and persistent laryngeal SCC is particularly dire.In this study, we sought to identify preoperative predictors of survival for patients with recurrent or persistent laryngeal SCC in order to set patient expectations and address modifiable risk factors. Identification of predictors of survival may also identify patients who could benefit from novel therapeutic agents in a neo/adjuvant fashion. Herein,we examine a cohort of patients with recurrent or persistent laryngeal SCC after definitive RT/CRT who has undergone total laryngectomy in order to identify potential preoperative predictors of clinical outcomes.

NCT ID: NCT02849314 Completed - Clinical trials for Recurrent Laryngeal Cancer

Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer

Start date: July 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to recurrent laryngeal cancer.

NCT ID: NCT01806675 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

Start date: March 4, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment.